People Need to File a Federal Court Lawsuit in the Eastern District of North Carolina Before August 8, 2024 Filing Deadline
(Posted by Tom Lamb at Drug Injury Watch)
Veterans who served at Camp Lejeune and their
Law Offices of Thomas J. Lamb, P.A.
Website:
https://www.drug-injury.com/
Law Offices of Thomas J. Lamb, P.A. Blogs
Blog Authors
Latest from Law Offices of Thomas J. Lamb, P.A.
Off-Topic Alert: Breast Implants Lymphoma Cancer ALCL Case Numbers Increasing Rapidly in the US
By Tom Lamb
New Estimates Reported in July 2022 Medical Journal Article Reveal BIA-ALCL is Diagnosed More Often as Time Goes On
(Posted by Tom Lamb at Drug Injury Watch)
A research letter published July 21, 2022 in JAMA Oncology,…
Using Copiktra for Leukemia or Lymphoma May Increase Risks of Serious Side Effects and Death
By Tom Lamb
Future FDA Advisory Committee Meeting Will Discuss Whether Copiktra Should be Used as CLL or SLL Treatment
(Posted by Tom Lamb at Drug Injury Watch)
As background, Copiktra (duvelisib) was approved by the FDA in 2018 to…
Xalkori Vision Disorders for Pediatric Patients in Clinical Trials Seen at Alarming Rate, Says EMA
By Tom Lamb
Drug Safety Warning: Ocular Toxicity and Severe Visual Loss Associated With Xalkori is Difficult to Detect in Children
(Posted by Tom Lamb at Drug Injury Watch)
Xalkori (crizotinib) is approved by the FDA for the treatment of:…
New FDA Regulatory Action for Ukoniq Drug Recall First Announced by Drug Company in April 2022
By Tom Lamb
June 2022 FDA Drug Safety Communication Makes Clear That Ukoniq Was Removed From Market Due to Safety Issues
(Posted by Tom Lamb at Drug Injury Watch)
On June 1, 2022, the FDA issued an update to the…
FDA Resources Online Available for Possible Drug Injury Research by Patients
By Tom Lamb
We Point Out One FDA Information Site and One FDA Database, Each of Which Are Good Starting Points
(Posted by Tom Lamb at Drug Injury Watch)
If you or someone you know experienced serious side effects that…
Ukoniq Drug Recall in April 2022 Comes Soon After FDA Warning About Increased Risk of Death in February 2022
By Tom Lamb
This “New” Lymphoma Drug Had Only Been on the Market Since February 2021, When Ukoniq Received FDA Accelerated Approval
(Posted by Tom Lamb at Drug Injury Watch)
In February 2022 we wrote about this Drug Safety Communication,…
Multiple Sclerosis (MS) Drugs Gilenya and Ocrevus Associated With a Higher Likelihood of Melanoma Skin Cancer
By Tom Lamb
Other MS Treatments Such as Lemtrada and Mayzent May Have an Increased Risk of Basal Cell Carcinoma and Squamous Cell Carcinoma
(Posted by Tom Lamb at Drug Injury Watch)
An analysis of skin cancers reported to the…
Fosamax Femur Fracture Federal Court MDL Lawsuits Are Dismissed For a Second Time in March 2022
By Tom Lamb
In a Long-Awaited Opinion, Federal Court Judge Wolfson Rules in Favor of Merck on Federal Preemption Legal Issue
(Posted by Tom Lamb at Drug Injury Watch)
On March 23, 2022, the federal court product liability lawsuits filed…
Ukoniq FDA Advisory Committee Meeting in April 2022 Will Evaluate Ukoniq Drug Safety Findings
By Tom Lamb
FDA Has Been Investigating Ukoniq for an Increased Risk of Death in Lymphoma Cancer Patients Treated With Ukoniq
(Posted by Tom Lamb at Drug Injury Watch)
In early February 2022 we learned this Drug Safety Communication, “…